219 related articles for article (PubMed ID: 27453300)
1. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
[TBL] [Abstract][Full Text] [Related]
2. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
3. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
5. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
6. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
Pinzone MR; Zanghì AM; Rapisarda L; D'Agata V; Benanti F; Spartà D; Nunnari G; Cacopardo B
Eur Rev Med Pharmacol Sci; 2014 Dec; 18(2 Suppl):11-5. PubMed ID: 25535185
[TBL] [Abstract][Full Text] [Related]
7. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
[TBL] [Abstract][Full Text] [Related]
8. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
9. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.
Trapero-Marugán M; Mendoza J; Chaparro M; González-Moreno L; Moreno-Monteagudo JA; Borque MJ; Moreno-Otero R
World J Gastroenterol; 2011 Jan; 17(4):493-8. PubMed ID: 21274379
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
12. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
13. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
15. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
16. IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
El Raziky M; Elsharkawy A; Said SE; Abdelatty S; El Akel W; Tantawy O; Gamal Eldeen H; Mabrouk M
J Interferon Cytokine Res; 2015 Aug; 35(8):649-53. PubMed ID: 25973761
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
[TBL] [Abstract][Full Text] [Related]
18. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
George SL; Bacon BR; Brunt EM; Mihindukulasuriya KL; Hoffmann J; Di Bisceglie AM
Hepatology; 2009 Mar; 49(3):729-38. PubMed ID: 19072828
[TBL] [Abstract][Full Text] [Related]
19. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
20. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
